Large study reveals Real-World outcomes for advanced breast cancer patients after initial therapy
NCT ID NCT06975371
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study analyzed data from 1,415 patients with a common type of advanced breast cancer (HR-positive, HER2-negative) whose first treatment stopped working. Researchers looked at how long patients lived without their cancer getting worse and overall survival after starting a second treatment. The goal was to understand real-world treatment patterns and outcomes using a large US database.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flatiron Health, Inc
New York, New York, 10013, United States
Conditions
Explore the condition pages connected to this study.